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Background: Carcinoids enter the differential diagnosis of the solitary pulmonary nodule. Bronchial carcinoids have
been traditionally considered as FDG-PET negative but recent studies have found an higher sensitivity of integrated
FDG-PET/CT for the detection of these neoplasms. The purpose of this study was to investigate the value of
integrated FDG-PET/CT for the evaluation of SPN suspected to be carcinoids.
Methods: All patients with pathologically proven bronchial carcinoids who had FDG-PET/CT scans between
2006 and 2012 have been retrospectively reviewed. PET/CT was performed with the same scanner and the same
technique for all patients. The following data were retrieved: age, sex CT findings (side, location, size, shape, margins),
SUVmax, type of operation, pathological findings (size and number of mitoses). Regarding PET findings, only SUVmax
was considered, whereas the visual assessment was not undertaken. Carcinoids were defined as typical and atypical
and as central and peripheral. The long-term follow-up was also recorded. The SUVmax was compared with the other
clinical, radiological and pathological variables to find any significant difference or correlation.
Results: Twenty-five patients were retrieved, 24 typical and one atypical carcinoid, 21 peripheral and 4 central
lesions. The mean diameter on CT-scan was 25.3 mm and the clinical size correlated well with the pathological size.
Sixty percent of the tumors were ovoid and 68% had smooth margins. The mean SUVmax was 3.6 (range 1.4-12.9).
All the lesions were completely resected. The regression analysis showed a direct correlation between the SUVmax
and the tumor size (p = 0.004). No further correlations were found between the SUVmax and the other variables.
None of the patients had recurrent disease or died during the follow-up.
Conclusions: Our study showed that FDG-PET/CT might be a useful tool in the evaluation of SPNs suspected to be
bronchial carcinoids. When a solitary pulmonary nodule shows an ovoid/round shape and smooth margins on the
CT scan and demonstrates an FDG uptake higher than that of the normal lung and with a SUVmax value >1-1.5, a
carcinoid should be suspected. If benign lesions can be presumably excluded, surgical resection or at least a biopsy
of the lesion is recommended.
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Bronchial carcinoids account for 1-2% of lung neoplasms
[1]. They are histologically classified as typical (low-grade
malignancies, accounting for 85-90% of all carcinoids) and
atypical (intermediate-grade) [2]. Eighty percent of pul-
monary carcinoids are endobronchial in origin and they
can be easily diagnosed by fiberoptic bronchoscopy biopsy,* Correspondence: alessandro.stefani@unimore.it
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reproduction in any medium, provided the orwhereas 20% occur peripherally and manifest as solitary
nodules or masses on chest imaging, usually in asymp-
tomatic patients [3]. These peripheral forms are part of
the differential diagnosis of solitary pulmonary nodule
(SPN). Imaging with somatostatin-receptor scintigraphy
could be used in cases of a suspected carcinoid [4,5] but,
when an SPN is found on a computed tomography (CT)
scan, many diseases other than carcinoid can be suspected,
such as lung carcinoma, hamartoma, inflammatory or
infectious lesions. Thus, in clinical practice, somatostatin-
receptor scintigraphy is not the examination of choiceLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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positron emission tomography (FDG-PET) is the preferred
examination in this setting [6]. More recently, integrated
FDG-PET/CT has been shown to be an effective tool to dif-
ferentiate malignant from benign lesions [7]. But carcinoids,
especially in the typical form, show a low metabolic activity
which reduces the sensitivity of FDG-PET for the diagnosis
of these neoplasms [8]. In fact, bronchial carcinoids have
been traditionally considered FDG-PET negative and this
understanding led many physicians to consider this tech-
nique as not a valuable tool for the diagnosis of these
tumors. Conversely, recent studies have found a higher
sensitivity of FDG-PET for the detection of carcinoids,
for both the typical and atypical forms [9-11], although
these studies have reported series with a limited number
of patients. Therefore, peripheral carcinoids presenting as
SPNs remain a diagnostic challenge.
The purpose of this study was to investigate the value
of integrated FDG-PET/CT for the evaluation of bron-
chial carcinoids by reviewing our institutional experience
since 2006.
Methods
Patients
We retrospectively reviewed all the patients with patho-
logically proven carcinoid tumors who had FDG-PET/
CT scans at our institution, between January 2006 and
December 2012.
The study was approved by the Institutional Review
Board of the University of Modena and Reggio Emilia.
At our institution FDG-PET/CT scanning was intro-
duced in 2006 and has been used in the preoperative
diagnostic and staging work-up of patients with SPN
suspected to be lung tumors. The following data were
retrieved from the clinical records of patients affected by
carcinoid who entered the study: age, sex, CT findings,
FDG-PET/CT findings, preoperative diagnosis (if available),
type of operation, number of mitoses and surgical stage.
Central carcinoid was defined if the tumor was visible
on the bronchoscopy examination, otherwise the tumor
was defined as peripheral, regardeless of its location
within the lung parenchyma. When the tumor was
visible on bronchoscopy, an endoscopic biopsy of the
lesion was undertaken.
Patients were referred to surgery because of the suspi-
cion of a malignant lesion, predominantly based on CT
and PET findings. Enhanced CT-scans were acquired with
helical technique in all patients, before FDG-PET/CT
examination. The indication to perform an FDG-PET/CT
was based on the results of CT scan. All patients under-
went surgical resection and the final diagnosis was based
on the histopathology of the surgical specimens. Lateral
muscle-sparing thoracotomy was the surgical approach.
Surgical resection was lobectomy or limited resection inall cases and mediastinal lymph node dissection was
routinely performed. A frozen section examination was
undertaken in all the cases without preoperative diagnosis.FDG-PET/CT
All the FDG-PET/CT scans were reviewed by nuclear
medicine experts, who were not blinded.
Whole-body FDG-PET/CT was performed with a com-
bined PET/CT scanner (GE Discovery DSTE, General
Electric medical systems, Milwaukee, WI, USA). This
scanner allows multi-detector row helical CT scanning
with 16 array of detectors. The technical parameters
used for the CT were as follows: a detector row config-
uration of 4 sections of 3.75 mm thickness, pitch of
1.375:1, KVp: 120, a gantry rotation speed of 0.8 s and
an amperage of 80–250 mA, modulated to maintain a
noise index of 30, in free breath. The CT examination
was used for attenuation correction of PET images.
The patients fasted for at least 6 hours prior to
the scan. After verification of serum glucose levels
of ≤ 150 mg/dl, the patients received an intravenous
injection of 3.7 MBq/Kg of FDG. The scans were started
60 to 70 minutes after the injection and scanned the area
from the base of the brain to the mid-thigh. The emission
PET scan was obtained with a 2.5 min acquisition per bed
position; typically, six or seven bed positions are obtained.
The scanner operates in the three-dimensional mode and
the images were reviewed in axial, coronal and sagittal for-
mats. For this study, visual analysis was not performed
and we considered only the tumor activity using the max-
imum standardized uptake value (SUVmax), to minimize
the partial volume effect on the uptake value. The SUV-
max is a semiquantitative measurement of tissue meta-
bolic rate and represents the maximum measured activity
at the region of interest (ROI), placed manually over the
most intense area of FDG accumulation, on the axial at-
tenuation corrected PET images.
CT images of both helical CT scan and integrated PET/
CT were analyzed for the tumor location, tumor size,
shape and margin characteristics, presence of calcifica-
tions, necrotic low-attenuation areas and associated post-
obstructive atelectasis or pneumonia. The tumor location
was expressed in terms of side and lobe and the tumor
size was defined by the longest diameter. The tumor shape
was classified as ovoid, round or lobulated and the tumor
margins as smooth or spiculated.Pathology
Typical carcinoids (TC) and atypical carcinoids (AC)
were defined on the basis of the current World Health
Organization criteria as follows [12]: TC has <2 mitotic
figures per 2 mm2 and no necrosis, whereas AC has 2 to
10 mitotic figures per 2 mm2 or evidence of necrosis.
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and expressed as N1 (hilar) or N2 (mediastinal).
Survival
The patients were routinely followed up at our institu-
tion and the survival data were available in our clinical
databases. Follow-up was updated on May 2013 for all
patients.
Statistical analysis
The objective of the study was to investigate the accur-
acy of FDG-PET/CT in the evaluation of bronchial car-
cinoids. The SUVmax of all the lesions was calculated
and compared with the other clinical, radiological and
pathological variables, to find any significant difference
or correlation.
The statistical analysis was conducted using the SPSS®
statistical software (Chicago, Ill, USA). Data were expressed
in terms of frequencies, mean and standard deviation (SD).
The comparisons were performed with the chi-square testTable 1 Clinical characteristics and PET/CT findings of the 25
Pts age sex
CT findings
Lobe location Lesion location Size (mm) Shape
1 78 F LUL Peripheral 12 ovoid
2 62 F LUL Peripheral 18 ovoid
3 64 F RML Peripheral 20 lobulated
4 29 F LLL Central 70 ovoid
5 36 F RML Peripheral 28 lobulated
6 67 F RML peripheral 15 ovoid
7 74 F LUL Peripheral 18 ovoid
8 51 F RML Peripheral 15 ovoid
9 49 F RML Peripheral 25 lobulated
10 61 M LUL Peripheral 23 ovoid
11 61 M LUL Central 42 ovoid
12 51 F LUL Peripheral 23 lobulated
13 61 F LLL Peripheral 20 ovoid
14 35 F LLL Peripheral 38 lobulated
15 60 F LLL Central 55 round
16 72 F RUL Peripheral 24 round
17 47 F LLL Central 40 ovoid
18 63 F RML Peripheral 14 lobulated
19 70 M LUL Peripheral 23 ovoid
20 61 F RUL Peripheral 13 lobulated
21 60 F RUL Peripheral 15 ovoid
22 60 F RML Peripheral 18 lobulated
23 78 F LUL Peripheral 16 ovoid
24 61 F RML Peripheral 34 ovoid
25 61 F LUL Peripheral 15 ovoidfor categorical variables and the t-test for continuous
variables. The correlation between SUVmax and size
was investigated using Spearman’s correlation coeffi-
cient and the goodness-of-fit measure of each linear
model (R2) was reported. A p value of less than 0.05 was
considered significant.
Results
Twenty-five patients presenting with SPN, having FDG-
PET/CT and undergoing subsequent surgical resection
for suspected malignancy were found to have bronchial
carcinoids.
The patients characteristics are presented in Table 1.
There were 22 women (88%) and 3 men, and mean age
was 58.8 years (range 29–78). No tumors showed fea-
tures of ectopic hormonal secretion (carcinoid or Cush-
ing syndrome). The left lung was involved in 14 cases
(56%); the left upper lobe and right middle lobe were
most frequently involved (9 and 8 cases, respectively).
Most of the lesions were located peripherally (21/25,patients
PET findings Surgical
procedure
Histologic findings
Margin SUVmax Cell type No of mitoses
smooth 1.9 Lobectomy Typical 1
smooth 4.6 Lobectomy Typical 1
smooth 12.9 Lobectomy Typical 1
spiculated 9.7 Lobectomy Typical 1
spiculated 4.2 Lobectomy Typical 1
spiculated 2.8 Lobectomy Typical 1
spiculated 2.4 Wedge resection Typical 1
smooth 1.9 Lobectomy Typical 1
smooth 6.0 Lobectomy Typical 1
smooth 1.5 Lobectomy Typical 1
smooth 2.2 Lobectomy Typical 1
spiculated 3.0 Lobectomy Typical 1
smooth 4.5 Segmentectomy Typical 0
smooth 5.0 Lobectomy Atypical 4
spiculated 4.2 Lobectomy Typical 1
smooth 3.1 Lobectomy Typical 1
smooth 2.0 Lobectomy Typical 1
smooth 2.4 Lobectomy Typical 1
spiculated 6.2 Wedge resection Typical 0
smooth 1.4 Lobectomy Typical 0
smooth 1.5 Wedge resection Typical 1
smooth 1.8 Wedge resection Typical 1
smooth 1.8 Lobectomy Typical 1
spiculated 3.1 Lobectomy Typical 1
smooth 1.7 Lobectomy Typical 1
Figure 1 The linear correlation model between the SUVmax
and tumor diameter shows a significant direct correlation.
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(range 12–70, SD 14 mm), and most tumors were ovoid
(n = 15, 60%) and had smooth margins (n = 17, 68%).
Necrotic areas, calcifications, atelectasis or obstructive
pneumonia were not found in any case.
The mean SUVmax of the nodules was 3.6 and the
median SUVmax was 2.8 (range 1.4-12.9, SD 2.7). The
FDG-PET did not reveal significant uptake in hilar or
mediastinal lymph nodes, and the CT scan was negative
for suspected node metastases in all cases.
Tissue diagnosis was obtained by bronchoscopic bi-
opsy, prior to surgical resection, in the 4 patients with
central lesions (16%); in these cases a diagnosis of sus-
pected carcinoid was achieved. In the other patients the
diagnosis was obtained by frozen section examination
and confirmed on histopathological analysis.
All the lesions were completely resected, in most cases
by lobectomy (20/25, 80%). The final diagnoses revealed
24 TCs and one AC. The mean pathological size was
24 mm (range 7–68, SD 14.9) and the pathological di-
mensions were comparable with the clinical dimensions
(p = 0.239). All the TCs showed one or no mitoses per
2 mm2, whereas the AC showed 4 mitoses per 2 mm2.
The patient with AC had one metastatic hilar lymph
node (N1) whereas the other cases were free of lymph
node involvement.
All the variables were compared and the differences
are as follows: regarding age and location, the patients
with central lesions were younger than those with per-
ipheral carcinoids (mean age 47 and 62 years respect-
ively, p = 0.033); concerning side and location, all the
central lesions were on the left side (p = 0.020); regard-
ing location and size, the central lesions were larger
than the peripheral ones (51.7 and 17.4 mm respect-
ively, p < 0.01). The bivariate regression analysis showed
a direct correlation between the SUVmax and the clin-
ical tumor size: Spearman’s rho 0.552, R2 0.30, p = 0,004
(Figure 1). Of the 11 tumors with a diameter <20 mm,
only 2 (18%) showed a SUVmax >2.5 (2.8 and 4.6), and
50% of the tumors with a diameter >30 mm showed a
SUVmax >2.5 (n = 3/6). A similar significant correlation
was found when pathological size was considered in the
regression analysis and compared to SUVmax. No fur-
ther correlations were found between the SUVmax and
the other clinical, radiological and pathological variables.
Follow-up was complete for all the patients, with a
mean of 43 months (range 12–74 months). None of the
patients had recurrent carcinoid disease or died during
the follow-up.
Discussion
Bronchial carcinoids enter the differential diagnosis of
SPN or mass. On the CT scan they typically present as
nodules or masses with an ovoid/round shape and smoothmargins [3]. However, also hamartomas, metastases,
infectious/inflammatory lesions or, in some cases, lung
carcinoma, can present this radiological aspect. On the
other hand, carcinoids can present with spiculated mar-
gins and irregular shape, although less commonly (8/25
patients, 32% in our series).
Because carcinoids express somatostatin receptors on
their surface, functional imaging with radiolabeled som-
atostatin analogues is the examination of choice [11,13].
In clinical practice, however, when a SPN or mass is de-
tected by CT scan, the diagnostic work-up is frequently
completed using FDG-PET, or, preferably, integrated FDG-
PET/CT, if available [14]. But pulmonary carcinoids have
been traditionally described as tumors with low grade of
FDG uptake, most likely because of their low metabol-
ism and slow growth. Therefore, FDG-PET has been
commonly understood to have a reduced sensitivity for
carcinoids and a limited role in the diagnostic work-up
of these lesions. This conviction originated from the
first work on FDG-PET and carcinoids by Erasmus in
1998 [8], who reported on 7 carcinoids, of which 6 were
hypometabolic (86%) and thus erroneously considered
benign. Later studies, however, did not confirm those
findings. Wartski described two carcinoids with intense
FDG uptake (SUVmax 4.8 and 10.6) [15]. Kruger re-
ported 13 carcinoids of which 54% were hypermetabolic
(SUVmax >2.5) [16]. Daniels studied 16 patients and
found a sensitivity for FDG-PET detection of carcinoids
of 75% [9]. Chong found that the uptake in 3 of 7 carci-
noids (43%) was higher than the mediastinal uptake and
they were considered positive on the PET/CT scan [10].
Kayani reported that 9 of 13 patients with carcinoids
(69%) showed significant FDG uptake and were consid-
ered to have malignant lesions [11]. Jindal found an overall
detection rate by FDG-PET/CT of 70% in a series of 20
carcinoids [13].
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utmost importance for an adequate evaluation of the
accuracy of FDG-PET for carcinoids. The sensitivity of
FDG-PET for carcinoids was generally investigated on
the basis of a visual assessment or of a SUVmax cut-
off. Regarding the visual assessment, the PET scan re-
sults were tipically interpreted as positive when the
nodule activity was greater than the background medias-
tinal pool activity (8–10). When the SUVmax was used to
define the PET positivity, a cut-off of 2.5 was commonly
applied [11,13,16]. Both methods of assessment of nodule
activity are derived from the evaluation of lung carcinoma
[17]. But carcinoids, especially the typical forms, show a
lower metabolic activity with respect to lung carcinoma,
therefore, a different method should be applied for the
evaluation of FDG uptake. We hypothesized that it may
be more appropriate to compare the nodule activity with
the normal lung and not with the mediastinal blood pool
activity, so that the majority of the nodules can be easily
visualized, as noted by Erasmus [8]. The evaluation of
SUVmax is mandatory with this method of assessment.
However, the cut-off value of 2.5 appears to be no longer
adequate, especially for TCs. As reported by other authors
[8,11,13,14], also in our series a number of TCs showed a
SUVmax <2.5 (12 patients of 24, 50%). If a cut-off of 1.5
was fixed, no false-negative results would have been
present in the series by Erasmus (0/6 patients) [8] and
Kayani (0/11) [11] and reduced false-negative rates of
23%, 8% and 4% would have been found in the series by
Jindal [13] and Kruger [16] and in our series, respectively.
FDG uptake of carcinoids was found to be related to
the histologic type, proliferation rate and size of the le-
sion. Several authors found that ACs showed a signifi-
cantly higher FDG uptake than TC and in many cases
this uptake was comparable to that of lung carcinoma
[9-11,13,15]. This is because ACs show high prolifera-
tion rates compared to TCs. Our series included 24 TCs
(96%) and one AC, thus an analysis based on the histo-
logic subtype was not feasible. Regarding the tumor size,
for lung carcinoma it is well known that the intensity of
the FDG uptake can be directly correlated to the tumor
dimensions [18,19]. Erasmus [8] and Kruger [16] dem-
onstrated that the SUVmax was directly related to theFigure 2 The integrated FDG-PET/CT reveals a small TC (20 mm) dem
and fused image.tumor diameter also for bronchial carcinoids. Also Daniels
reported the correlation between the FDG uptake and the
size of the neoplasm but the SUVmax was not calculated
in his work [9]. In our series we found a direct correlation
between the SUVmax and the size of the tumor, when
both the clinical and pathological diameters were investi-
gated (Figure 1). This relationship may partly explain the
variability in the FDG uptake in our series of TCs (SUV-
max range 1.4 – 12.9), although some exceptions are
present (Figures 2 and 3). We did not find any association
between the SUVmax and other tumor features, such as
location, shape or margins; similar associations have not
been reported in the literature.
Some authors found a correlation between the staging
of lung carcinoids by FDG-PET and surgical staging
[9,10]. In our series, FDG-PET was negative for nodal
metastases in all patients. This finding correlated well with
the pathological findings, because all the patients resulted
pN0, except for the AC patient, who had pN1 disease.
However, because our series lack of a comparison group
of N + patients, conclusions regarding PET utility for
nodal disease remain uncertain.
In our study, 4 patients received a preoperative diag-
nosis of TC by fiberoptic bronchoscopy. It is generally
accepted that FDG-PET is not mandatory in the clinical
evaluation of patients with biopsy-proven pulmonary car-
cinoid [9,11] and we agree with this statement. Our series
includes patients with biopsy-proven TC only because
they underwent PET/CT before bronchoscopy during
their staging work-up. The disproportionate number of
peripheral carcinoids in our study population reflects
the clinical policy to consider that PET/CT is not neces-
sary in cases of a preoperative diagnosis of bronchial
carcinoid, which is usually obtained in central forms by
bronchoscopy.
Long-term prognosis for patients affected by TC is
favourable, with 5-year survival rates higher than 95%
after radical surgical resection [20]. This rate is consistent
with our findings, which showed no deaths or recurrences
of carcinoid disease at follow-up.
In our study, all the lesions were clearly detectable as
SPNs on helical CT. In many cases, ovoid/round shape
and regular margins suggested a carcinoid, and the mainonstrating high uptake (SUVmax 12.9). From left to right: CT, PET
Figure 3 The integrated FDG-PET/CT reveals a large TC (42 mm) demonstrating low uptake (SUVmax 2.2). From left to right: CT, PET and
fused image.
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nign lesions. In a minority of cases, spiculated margins
and irregular shape led to inclusion of lung carcinoma in
the differential diagnosis. All of these lesions showed
FDG uptake, therefore none was considered typically be-
nign, and we proceeded to surgical resection in all cases.
For the lesions with a lower uptake, a diagnosis of hamar-
toma was considered unlikely, because the FDG uptake is
exceptional for hamartomas [21,22]; infections or inflam-
matory lesions remained in the differential diagnosis but
they were considered less probable than carcinoids after a
careful examination of the patient. Regarding the lesions
with a higher uptake, a diagnosis of lung carcinoma,
particularly a low-grade adenocarcinoma, was taken into
account; in these latter cases, a further unconfirmed suspi-
cion of carcinoid would not have affected the adequacy
of the surgical indication.
The assessment of the nodule characteristic was per-
formed analysing the images of enhanced helical CT-scan
rather than CT images of the integrated PET/CT scan.
The acquisition parameters of CT scan of the integrated
PET/CT are not adequate for a careful assessment of the
nodule features, especially for small lesions. Moreover, the
enhanced helical CT scan is usually the first approach to
the SPN following the chest-x-ray and, therefore, is avail-
able for all patients.
The main limitation of this study is its retrospective
nature. The data only included nodules that were resected
and may underestimate the number of PET false-negative
lesions.Conclusions
We believe that for cases in which an SPN with an
ovoid/round shape and smooth margins on the CT scan
reveals an FDG uptake higher than that of the normal
lung and with a SUVmax value >1-1.5, a bronchial car-
cinoid should be considered and surgical resection or at
least a biopsy of the lesion should be recommended.
Further studies comparing the PET/CT findings of car-
cinoids, hamartomas, low-grade adenocarcinomas and
infectious/inflammatory lesions should be advocated.Abbreviations
18F-FDG-PET: 18F-fluorodeoxyglucose positron emission tomography;
AC: Atypical carcinoids; CT: Computed tomography; ROI: Region of interest;
SD: Standard deviation; SPN: Solitary pulmonary nodule; SUV: Standardized
uptake value; TC: Typical carcinoids.
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